Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review.
Efficacy of management strategies for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review. Asia Pac J Clin Oncol. 2018 Jan 30;: Authors: Nahm N, Mee S, Marx G Abstract Aromatase inhibitors are the gold standard in the treatment of hormone receptor-positive breast cancer, but lead to an arthralgia syndrome which is implicated in 13-22% of noncompliance. This is the first systematic review of the efficacy of existing management strategies for this side effect. Eligible studies were retrieved from computer searches of Medline, Cochrane and Embase and the significant intervention groups were identified. The risk of bias of selected studies was evaluated and the relevant data items were extracted, summarized and analyzed. A total of 21 studies were discussed in this review representing 12 different interventions. While several trials had positive findings, the major methodological limitations of the studies meant that no definitive evidence could be found supporting any of the interventions. Future trials are needed which address the methodological problems identified in this review. Exercise holds promise for future research based on its proven benefit in breast cancer. PMID: 29380528 [PubMed - as supplied by publisher]
The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis.
With a sophisticated new algorithm, scientists have found a way to forecast an individual ’ s risks for five deadly diseases.
From time to time I have commented on the controversies over cancer screening. Most people assume that screening is an unqualified good, that early detection of cancer saves lives. Whenever some panel proposes recommending less screening, we hear screaming and yelling from advocates who claim they are trying to " ration " health care to save money at the expense of people's lives.In fact,as a bunch of Australians and a Minnesotan explain in BMJ, there are a few conditions called " cancer " that you are better off not treating, or perhaps treating very conservatively. These include what is called ductal ...
ConclusionIt is important to be aware of this entity of epidermoid cyst mimicking breast cancer, and the treatment options available in these cases.
Mohammad O. E. Abdallah, Ubai K. Algizouli, Maram A. Suliman, Rawya A. Abdulrahman, Mahmoud Koko, Ghimja Fessahaye, Jamal H. Shakir, Ahmed H. Fahal, Ahmed M. Elhassan, Muntaser E. Ibrahim, Hiba S. Mohamed
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies being developed for the treatment of breast cancer. Dr Burris touches ... Author: VJOncology Added: 08/13/2018
Data from the American College of Radiology's National Mammography Database...Read more on AuntMinnie.comRelated Reading: Women dubious about risk-based breast cancer screening Provider factors influence breast cancer screening Shared decision-making for mammography could be clearer Gap narrows in black, white breast cancer death rates Mammography database makes performance tracking easier
(Broad Institute of MIT and Harvard) A research team reports a new kind of genome analysis that could identify large fractions of the population who have a much higher risk of developing serious common diseases, including coronary artery disease, breast cancer, or type 2 diabetes. These tests, which use information from millions of places in the genome to ascertain risk for five diseases, can flag greater likelihood of developing the potentially fatal conditions well before any symptoms appear.
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00540
The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitorThe role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor, Published online: 13 August 2018; doi:10.1038/s41388-018-0438-2The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor